Pfizer will acquire biotech group Biohaven Pharmaceuticals for $11.6 billion, marking its biggest deal since 2016. Biohaven's Rimegepant medication, used as both a treatment and preventative for migraines, is expected to bring in sales of over $4 billion by 2030. This comes as Pfizer expects sales of its COVID-19 vaccines to drop from last year's highs.